Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Importance: Tumor Treating Fields (TTFields) are an anti-mitotic treatment approved for treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in glioblastoma comprise alternating electric fields (200 kHz) delivered continuously, ideally for ≥18 h/day, to the tumor bed via t...
Main Authors: | Mario E. Lacouture, Milan J. Anadkat, Matthew T. Ballo, Fabio Iwamoto, Suriya A. Jeyapalan, Renato V. La Rocca, Margaret Schwartz, Jennifer N. Serventi, Martin Glas |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01045/full |
Similar Items
-
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
by: George Ansstas, et al.
Published: (2016-01-01) -
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
by: Guangrong Lu, et al.
Published: (2019-01-01) -
Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
by: H. Ian Robins, et al.
Published: (2018-10-01) -
Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial
by: N. Guberina, et al.
Published: (2020-04-01) -
Tumor-Treating Fields Therapy for Pediatric Brain Tumors
by: Atsushi Makimoto, et al.
Published: (2021-04-01)